A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Orange Biomed Launches in U.S. Market to Reduce Inaccuracies in Diabetes Diagnosis for Minorities and Help Manage Diabetes at Home with a Revolutionary POC A1c Test

Orange Biomed—a healthcare startup with cutting-edge diabetes management technology—announced its U.S. launch today with a mission to fill critical testing gaps for people with pre-diabetes and diabetes. Orange Biomed is currently conducting studies of OBM rapid A1c, the world’s first glycated hemoglobin analyzer through single-cell analysis of red blood cells. Orange Biomed is set to unveil its latest technology at the 83rd Scientific Sessions of the American Diabetes Association (ADA), to be held in San Diego, CA, in June 2023.

“Current technologies are likely to produce inaccurate A1c results disproportionately more for non-white patients due to hemoglobin variants,” explains Co-Founder Yeaseul Park. “Hemoglobin variants are more common in patients with African, South and Southeast Asian, and Mediterranean ancestry. Inaccurate results can delay diabetes diagnosis and serious long-term health damage. We invented a new method of A1c testing, free from hemoglobin variant interference, to facilitate earlier detection and management of diabetes across all patient populations.”

Park continued, “OBM rapid A1c is a portable, guided, five-minute test requiring only a single drop of blood to produce accurate results. By seamlessly integrating lab-level technology into portable devices, we seek to make healthcare more accessible, accurate, and affordable for everyone.”

In pre-series A funding rounds, Orange Biomed has exceeded $2M in cumulative investments. OBM rapid A1c is currently undergoing global studies with Asan Medical CenterOrange Biomed is seeking FDA clearance within a year.

The latest technology will be unveiled at the ADA’s 83rd Scientific Sessions from June 24-26. Stop by presentation number 954-P in the Poster Hall to learn more. U.S. medical organizations and research centers interested in conducting trials of OBM rapid A1c are advised to reach out here.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy